Track Edgewise Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Edgewise Therapeutics, Inc. EWTX · Stock Open Edgewise Therapeutics, Inc. in new tab

45.93 USD
P/E
5.82
EPS
8.38
P/B
3.27
ROE
92.14
Beta
0.40
Target Price
55.42 USD
Loading chart...
Key Metrics
Earnings dateFeb. 25, 2027
P/E5.82
EPS8.38
Book Value14.92
Price to Book3.27
Debt/Equity0.21
% Insiders0.483%
Estimates
Forward P/E-25.99
Forward EPS-1.88
Target Mean Price55.42

DCF valuation

Model fair value for Edgewise Therapeutics, Inc. (EWTX)
Result
Sign in to run the valuation for EWTX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
12 analysts · consensus Strong buy · mean target 55.42 USD (low 36.00, high 85.00) · as of 10 Nov 2026
Low 36.00
Mean 55.42
High 85.00
Price 45.93
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Edgewise Therapeutics, Inc. Logo Edgewise Therapeutics, Inc. Analysis (EWTX)

United States Health Care Official Website Stock

Is Edgewise Therapeutics, Inc. a good investment? Edgewise Therapeutics, Inc. (EWTX) is currently trading at 45.93 USD. Market analysts have a consensus price target of 55.42 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 5.82. This relatively low multiple may signal that Edgewise Therapeutics, Inc. is undervalued compared to historical market norms.

Earnings Schedule: Edgewise Therapeutics, Inc. is expected to release its next earnings report on Feb. 25, 2027. The market consensus estimate for Forward EPS is -1.88.

Investor FAQ

Does Edgewise Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Edgewise Therapeutics, Inc.?

Edgewise Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 25, 2027. The company currently has a trailing EPS of 8.38.

Company Profile

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Exchange Ticker
NMS (United States) EWTX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion